This article looks at the 14 Best Multibagger Penny Stocks to Buy Right Now.
The Russell 2000 Index has hit fresh highs heading into 2026, signaling renewed interest in small companies. The index is already up by more than 13% for the year as market rotation from large-cap stocks gathers pace.
The renewed focus on penny and small-cap stocks comes as investors rotate into higher-risk, higher-reward assets. The shift also underscores growing confidence in the broader economy and corporate sector, as they are expected to deliver growth amid the ongoing US Federal Reserve easing cycle.
After lagging for years as mega-cap and AI-driven stocks surged, small caps and penny stocks have become relatively undervalued. Similarly, interest in small companies has picked up amid the view that monetary policy is no longer tightening.
A third Federal Reserve rate cut and the prospect of more easing to come are fuelling interest in small companies, as the Russell 2000 Index is outperforming the S&P 500 heading into year-end. Strategists at Bank of America Corp., JPMorgan Chase & Co., BTIG LLC, and Polar Capital America Corp expect the rotation to extend into 2026.
“Small caps are a good place to be generally, and globally, in part because they’ve been overlooked for a long period of time,” said Dan Boston, head of the global small company team at Polar Capital America. “What we see going forward is small caps doing well vis-a-vis large caps.”
According to Jonathan Krinsky, managing director and chief market technician at BTIG, investors are set to take some profits from big tech in 2026 amid concerns about high valuations. Consequently, let’s take a look at some of the best multibagger penny stocks to buy right now.
Our Methodology
To compile our list of the best multibagger penny stocks to buy right now, we used Finviz screener and CNN to identify stocks trading for less than $5 a share (as of December 16). We focused on penny stocks with an upside potential of more than 100% and that were popular among elite hedge funds in the third quarter of 2025. Finally, we ranked the stocks in ascending order based on their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best Multibagger Penny Stocks to Buy Right Now
14. ADC Therapeutics S.A. (NYSE:ADCT)
Share price: $4.18
Analysts upside potential: 102.11%
Number of hedge fund holders: 19
ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst Michael Schmidt reaffirmed his Buy rating on ADC Therapeutics (NYSE:ADCT) and set a price target of $10.00. On December 3, RBC Capital reiterated an Outperform rating and $5.00 price target in response to interim Phase Ib data from the LOTIS-7 trial.
Data from the LOTIS-7 trial evaluating the safety and efficacy of ZYNLONTA demonstrated a manageable safety profile and strong efficacy, including deep and durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
The trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% across 49 efficacy-evaluable patients. The topline results affirm the potential of ZYNLONTA and glofitamab as the best-in-class bispecific antibody-based combination in 2L+ DLBCL.
“Taken together with the LOTIS-5 trial, for which top-line results are anticipated in the first half of 2026, we believe ZYNLONTA-based combinations offer complementary approaches with the potential to improve outcomes for 2L+ DLBCL patients,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
Amid positive trial results, ZYNLONTA has already received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma.
ADC Therapeutics S.A. (NYSE:ADCT) is a commercial-stage biotech company that develops targeted cancer drugs called Antibody-Drug Conjugates (ADCs), using its proprietary Pyrrolobenzodiazepine (PBD) technology. It uses the technology to link potent chemotherapy to antibodies that find and kill cancer cells, with an approved drug (Zynlonta) for lymphoma.
13. Repay Holdings Corporation (NASDAQ:RPAY)
Share price: $3.40
Analysts upside potential: 105.88%
Number of hedge fund holders: 21
Repay Holdings Corp (NASDAQ:RPAY) is one of the best multibagger penny stocks to buy right now. Repay Holdings (RPAY) holds a Moderate Buy rating, with a $7 average target (range $4–$12), implying ~106% upside from the current price.
On November 20 at the Stephens Annual Investment Conference, the company reiterated its focus on expanding its market presence and enhancing its technology offerings. The remarks come as the company continues to move from negative growth and margin pressures.
In a bid to accelerate growth, Repay Holdings is increasingly investing in technology and sales development to drive future growth. It’s also accelerating its focus on business-to-business payments and consumer engagement through innovative solutions. The push is part of an effort to bolster EBITDA margins and achieve free cash flow of over 50%.
“During the third quarter, REPAY achieved solid normalized growth with strong Adjusted EBITDA margins and robust Free Cash Flow generation. We opportunistically deployed capital towards our organic growth initiatives, repurchased shares, and retired a significant portion of convertible notes,” said John Morris, Chief Executive Officer of REPAY.
Some of the drivers expected to accelerate growth include digital transformation in payments and the business back office. In addition, the company has set its sights on capitalizing on market opportunities in the $5.6 trillion market, with a focus on non-discretionary transactions.
Repay Holdings Corporation (NASDAQ:RPAY) is a payment technology company offering integrated solutions for businesses to accept and send electronic payments, serving sectors like personal loans, auto finance, and B2B, through its Consumer and Business Payments segments.
12. American Bitcoin Corp (NASDAQ:ABTC)
Share price: $1.61
Analysts upside potential: 124.72%
Number of hedge fund holders: 5
American Bitcoin Corp (NASDAQ:ABTC) is one of the best multibagger penny stocks to buy right now. On December 10, Roth MKM analyst Darren Aftahi began coverage of American Bitcoin Corp (NASDAQ:ABTC) with a Buy rating and a $4.00 price target.
On December 10, the company bolstered its Bitcoin holdings to 4,783 with the acquisition of 416 BTC coins. The accumulation includes Bitcoin acquired through mining operations and strategic purchases. It also includes Bitcoin held in custody or pledged under an agreement with Bitmain for miner purchases.
Following the purchase, American Bitcoin also updated its Satoshis Per Share (SPS) metric to reflect the amount of Bitcoin attributable to each outstanding share of common stock. The update shows a 17% increase over the past month in the Satoshi per Share metric.
“With our Bitcoin reserve now at 4,783, we continue to scale at an exceptional pace. SPS grew more than 17% in just over a month, and we added 416 Bitcoin in the past week—evidence of the strength and efficiency of our strategy,” said Eric Trump, Co-founder and Chief Strategy Officer of American Bitcoin. “In the three months since we listed on Nasdaq, we have built one of the largest and fastest growing Bitcoin accumulators, supported by a cost structure and margin profile that positions us for long term value creation. We remain laser-focused on advancing our strategy and building on this momentum in the months ahead.”
The company continues to bolster its Bitcoin reserves on the heels of delivering impressive third-quarter results, whereby revenue more than doubled quarter over quarter to $64.2 million. Gross margins also expanded 7% points to 56%. Net income came in at $3.5 million, a slight improvement from $3.4 million. The solid Q3 results follow increased strategic focus on expanding mining operations and increasing efficiency.
American Bitcoin Corp (NASDAQ:ABTC) is an American Bitcoin mining and treasury management company, majority owned by Canadian miner Hut 8 Mining. It provides computing power to mining pools, which use it to operate nodes and validate blocks on the blockchain.
11. Absci Corporation (NASDAQ:ABSI)
Share price: $3.39
Analysts upside potential: 143.36%
Number of hedge fund holders: 18
Absci Corporation (NASDAQ:ABSI) is one of the best multibagger penny stocks to buy right now. On December 12, Needham’s Gil Blum reiterated a Buy rating on Absci Corporation (NASDAQ:ABSI) with a $7 price target, citing encouraging preclinical data for ABS‑201 in androgenetic alopecia and strong market interest ahead of the planned HEADLINE study. Earlier, on December 4, JonesTrading also maintained a Buy rating with a $9 target.
A day earlier, on December 11, the company delivered topline preclinical data for its artificial intelligence-designed antibody ABS-201. The data have confirmed the drug’s potential to stimulate hair growth in human scalp tissue samples.
ABS-201 edge stems on its ability to target the prolactin receptor to promote hair growth while preserving stem cells. It also prolongs anagen by blocking catagen and promoting hair matrix keratinocyte proliferation. It has also shown potential to extend the active growth phase of hair follicles.
“Today’s standard treatment options for androgenetic alopecia (AGA) do not target one of its root causes, the reduced capacity of hair follicle stem cells to generate progenitor cells, and largely ignore the role of other hormones than androgens in this form of hair loss,” said Professor Ralf Paus, Research Professor of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine.
Paus expects ABS-201 to open a radically new chapter in future AGA management by targeting a key mechanism in androgenetic alopecia (pattern hair loss) that current treatments do not. The candidate drug is also staring at a significant market given that Androgenetic alopecia affects approximately 80 million Americans.
Absci Corporation (NASDAQ:ABSI) is a clinical-stage biopharmaceutical company that uses a proprietary generative artificial intelligence (AI) drug creation platform to discover and develop novel protein-based therapeutics, or biologics.
10. Bit Digital, Inc. (NASDAQ:BTBT)
Share price: $2.25
Analysts upside potential: 161.33%
Number of hedge fund holders: 20
Bit Digital Inc. (NASDAQ:BTBT) is one of the best multibagger penny stocks to buy right now. On December 5, Bit Digital Inc. (NASDAQ:BTBT) announced it acquired 506.25 ethereum in November at an average price of $3,045.11. It exited the month with about 154,398.7 ethereum valued at about $461.9 million.
During the month, the company staked an additional 5,141 ETH, bringing total staked ethereum to about 137,621, representing 89.1% of its total holdings. Staking generated about 328.5 Ethereum, representing an annualized return of about 3.05%. The company began staking in 2022, and its operations have ballooned to about 15,146 ETH and ETH equivalents in externally managed funds. In addition to Ethereum holdings and staking, the company holds about 27 million WhiteFiber (WYFI) shares valued at about $579.5 million.
Meanwhile, on November 17, analysts at H.C. Wainwright reiterated a Buy rating on the stock with a $7 price target. The positive stance was in response to a solid third-quarter report that showed a 20% sequential increase in revenue to $30.5 million. The revenue increase was bolstered by Ethereum staking, which jumped to $2.9 million in the third quarter from $0.4 million in the second quarter. The revenue increase also came as the company increasingly reduced its Bitcoin mining operations to focus on Ethereum.
Bit Digital, Inc. (NASDAQ:BTBT) is a digital asset platform focused on high-performance computing for AI and Ethereum staking, having pivoted from its initial Bitcoin mining operations. It also builds and offers scalable AI cloud infrastructure using GPUs, provides Ethereum staking services for native yield, and develops data centers in North America and Iceland.
9. Hive Digital Technologies Ltd. (NASDAQ:HIVE)
Share price: $3.06
Analysts upside potential: 185.95%
Number of hedge fund holders: 9
HIVE Digital Technologies Ltd (NASDAQ:HIVE) is one of the best multibagger penny stocks to buy right now. On December 11, HIVE Digital Technologies Ltd (NASDAQ:HIVE) listed on the Colombian Stock Exchange, marking the first Bitcoin and AI infrastructure company to do so. The firm posted record quarterly revenue of $87.3 million, up 285% year‑over‑year, and is expanding its Paraguay operations with 25+ Exahash mining capacity, plans for 36,000 GPUs, and 400 MW of renewable energy. Already listed in Canada, Germany, and the U.S., the move broadens its global presence.
On December 10, the company announced record Bitcoin production of 290 in November, representing a 182% year-over-year increase. The record production came from the company, achieving an average daily output of 9.7 Bitcoin at an average hashrate of 23.5 Exahash per second. Fleet efficiency stood at 17.5 joules per Terahash. The record production also came on the heels of the company’s commissioning of its final ASICs at the Valenzuela campus in Paraguay. Its total capacity in Paraguay has risen to 300 megawatts.
On November 21, B. Riley’s Nick Giles cut Hive Digital’s (HIVE) price target to $7 from $8 but kept a Buy rating, citing strong Q3 EBITDA from lower power costs, progress in BTC mining and AI cloud build‑out, and attractive HPC asset valuations with catalysts ahead in GPU deployment and colocation.
Hive Digital Technologies Ltd. (NASDAQ:HIVE) builds and operates green data centers for Bitcoin mining and High-Performance Computing (HPC) / AI cloud services, using clean energy like hydroelectric power to provide scalable, environmentally responsible digital infrastructure for both cryptocurrency and artificial intelligence workloads.
8. Gevo, Inc. (NASDAQ:GEVO)
Share price: $2.20
Analysts upside potential: 191.82%
Number of hedge fund holders: 7
Gevo, Inc. (NASDAQ:GEVO) is one of the best multibagger penny stocks to buy right now. On December 1, analysts at Northland initiated coverage of Gevo, Inc. (NASDAQ:GEVO) with an Outperform rating and a $3 price target.
The research firm remains confident about the company’s long-term prospects, as it continues to strengthen its position as a low-carbon renewable fuels producer. The company boasts of an ethanol plant with collocated carbon capture and sequestration capabilities. According to the research firm, the commercialization of Alcohol-to-Jet Sustainable Aviation Fuel technology also affirms the company’s growth prospects.
Meanwhile, on December 15, Gevo announced a strategic leadership transition as it seeks to position itself for continued growth and innovation. Dr. Paul Bloom will take over as the company’s Chief Executive Officer on April 1, 2026, succeeding long-standing Chief Executive Officer and board member, Dr. Patrick Gruber. Dr. Bloom has reiterated his commitment to taking the company to the next phase of critical growth once he takes over as CEO.
“Our team is committed to delivering cost-effective fuels, chemicals, and carbon management solutions that create value for our customers and shareholders. Pat’s vision and dedication have established Gevo as a global leader in our industry. My focus will be on increasing profitability from our active businesses while leveraging our technology, business system, and intellectual-property portfolio to accelerate Gevo’s growth,” said Dr. Bloom.
Gevo, Inc. (NASDAQ:GEVO) is a renewable chemicals and advanced biofuels company that creates low-carbon, sustainable alternatives to petroleum-based products, using bio-based feedstocks like corn to produce fuels (jet fuel, gasoline components, diesel) and chemicals (plastics precursors) while also generating protein for the food chain and renewable natural gas (RNG).
7. Annexon, Inc. (NASDAQ:ANNX)
Share price: $4.91
Analysts upside potential: 195.32%
Number of hedge fund holders: 22
Annexon Inc. (NASDAQ:ANNX) is one of the best multibagger penny stocks to buy right now. On December 1, Clear Street initiated coverage of Annexon Inc. (NASDAQ:ANNX) with a Buy rating and a $17 price target. The positive stance is in response to the progress the company has made in developing complement inhibitors for inflammation-related diseases.
The company’s lead asset, vonaprument, for geographic atrophy (GA) has already demonstrated positive results in Phase 2 trials. The research firm expects topline pivotal data in the second half of next year, which should provide clinical de-risking and access to a large and growing market. The company’s other lead product, Tanruprubart, for Guillain-Barré syndrome (GBS), has also delivered positive data in a pivotal study, with an European regulatory submission scheduled for early next year.
Clear Street has also mentioned the oral complement inhibitor ANX1502, which is currently in early clinical development. The research firm expects it to be an essential treatment in a class presently limited to injected or infused administration.
Meanwhile, analysts at Wells Fargo reiterated an overweight rating on the stock on November 19 and raised the price target to $27 from $14. The price target increase reflects the research firm’s confidence that Vonaprument’s Phase 3 GA trial will deliver positive results in the second half of 2026.
Annexon, Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company developing next-generation medicines, primarily targeting the classical complement pathway (C1q) to treat severe autoimmune, neurodegenerative, and ophthalmic diseases, such as Guillain-Barré Syndrome (GBS) and geographic atrophy (GA).
6. Geron Corporation (NASDAQ:GERN)
Share price: $1.33
Analysts upside potential: 200.75%
Number of hedge fund holders: 37
Geron Corporation (NASDAQ:GERN) is one of the best multibagger penny stocks to buy right now. On December 11, the company announced a strategic restructuring plan to lower its operating expenses. It plans to reduce its workforce by a third as it aims to streamline operations while maintaining focus on core priorities.
The restructuring drive is scheduled to be completed in the first quarter of next year and will result in lower operating expenses in 2026. The restructuring will also result in significant cost savings starting in the first quarter. However, the company is also poised to incur cash-based expenses.
“After my first four months at Geron, the leadership team and I have assessed the business with the goal of streamlining our organizational structure to advance our strategy and create long-term value,” said Harout Semerjian, President and Chief Executive Officer of Geron.
In addition to cost savings, the company remains focused on commercializing RYTELO, its flagship treatment for anemia in adults. The company is already exploring commercial opportunities outside the US as it continues to advance a Phase 3 ImpactMF trial.
Meanwhile, analysts at H.C. Wainwright reiterated a Neutral rating on the stock, buoyed by expectations that the company’s operating expenses will drop in 2026 once the cuts are implemented. Consequently, the research firm expects the company to achieve profitability by the second half of next year.
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing treatments for blood cancers, primarily by targeting and inhibiting the enzyme telomerase, which is crucial for cancer cell survival.
5. Atai Life Sciences N.V. (NASDAQ:ATAI)
Share price: $4.18
Analysts upside potential: 204%
Number of hedge fund holders: 21
Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy right now. ATAI Life Sciences holds a Strong Buy consensus from 8 analysts, with a 12‑month average target of $12.71 (range $10–$16), implying a 204% upside from the current $4.18.
On December 11, the United States Patent and Trademark Office granted Atai Life Sciences N.V. a new patent for EMP-01, an oral formulation for the treatment of social anxiety disorder. The patent covers the drug substance of EMP-01 and will provide exclusivity through 2043.
The patent identifies a highly crystalline thermodynamically stable HCl salt form of (R)-MDMA with high aqueous solubility and low hygroscopicity. The patent is poised to support the company’s strategy to develop innovative, differentiated therapies for addressing significant mental health needs.
EMP-01 is currently in clinical development for social anxiety disorder, with exploratory Phase 2a underway. The company is on course to deliver topline data in the first quarter of next year, as the drug has already demonstrated a unique dose-dependent effect profile in Phase 1 trials.
“EMP-01 is an important asset in our pipeline, and securing this patent issuance in the U.S. further strengthens our ability to advance the program while delivering meaningful value for patients and shareholders. We look forward to reporting topline data from the exploratory Phase 2a study evaluating EMP-01 in adults with social anxiety disorder in the first quarter of 2026,” said Chief Executive Officer and Co-founder of AtaiBeckley.
Atai Life Sciences N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on creating novel mental health treatments, primarily using psychedelic-based therapies like DMT (VLS-01) and R-MDMA (EMP-01) for conditions like treatment-resistant depression (TRD) and social anxiety, aiming for rapid, effective, and scalable solutions to address gaps in current mental healthcare.
4. ImmunityBio Inc. (NASDAQ:IBRX)
Share price: $2.36
Analysts upside potential: 210.59%
Number of hedge fund holders: 18
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at Jefferies raised the stock’s price target to $9 from 8 while reiterating a Buy rating.
The price target hike follows the European Medicines Agency’s issuance of a conditional marketing authorization for Anktiva, the company’s flagship treatment option for non-muscle-invasive bladder cancer with carcinoma in situ (NMIBC-CIS).
The EMA authorization also comes on the heels of the company securing approvals for the treatment in the US and the UK. The approval expands the company’s geographic and commercial presence. The approval also covers the use of the therapy in combination with Bacillus Calmette-Guerin. It marks the first time that such a treatment has received authorization in the European Union.
Anktiva is poised to address a significant issue, given that patients with invasive bladder cancer have limited treatment options beyond surgical removal. Bladder Cancer is a serious health condition in the European Union, ranked as the fifth most common cancer.
“ANKTIVA represents an important evolution in the treatment of NMIBC CIS, strengthening the immune response and improving the durability of BCG,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio. “Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible, to ensure avoidance of a radical cystectomy.
ImmunityBio Inc. (NASDAQ:IBRX) is a clinical-stage biotech company developing next-generation immunotherapies and cell therapies to harness the body’s immune system against cancers and infectious diseases, notably with their FDA-approved drug ANKTIVA for bladder cancer, which activates immune cells for long-lasting responses, and by exploring treatments for long COVID.
3. Rezolve AI PLC (NASDAQ:RZLV)
Share price: $2.57
Analysts upside potential: 300%
Number of hedge fund holders: 14
Rezolve AI PLC (NASDAQ:RZLV) is one of the best multibagger penny stocks to buy right now. On December 3, the company announced plans to expand its stablecoin payment capabilities to North America, the UK, and Europe.
The expansion follows successful implementation in Brazil, where the company processed over $1 billion in USDT and Bitcoin transactions, affirming consumer and merchant adoption of digital assets. The proposed expansion will build on the existing enterprise’s presence across the retail fashion, finance, and hospitality sectors.
“Rezolve has had an exceptional year of growth with major Western enterprises already deploying our AI-driven commerce platform. Crownpeak is expected to strengthen and accelerate what was already working, giving us deeper integration points and wider distribution for rolling out stablecoin payments across markets where we already have meaningful traction. Our ecosystem also now includes the high-performance on-chain data capabilities of Subsquid (SQD), giving us the long-term infrastructure required to support agentic and stablecoin transactions at true global scale, well ahead of the industry curve.”
Expansion into North America, the UK, and Europe also builds on the acquisition of digital experience platform Crownpeak. The acquisition is expected to enhance the company’s ability to enable stablecoin payments. Crownpeak joins the company with more than 400 enterprise deployments across multiple geographies and sectors.
On December 2, H.C. Wainwright analyst Scott Buck reiterated a Buy rating on Rezolve AI with a $10 price target, highlighting the Crownpeak acquisition as a key driver of growth. The deal is expected to add $70 million in annual revenue, deliver immediate EBITDA benefits, and create cross‑selling opportunities with major brands like Sephora and Calvin Klein. Buck believes the move strengthens Rezolve’s path toward exceeding its 2025 ARR target and achieving $500 million ARR by 2026, noting that despite initial market skepticism, the company’s M&A strategy and AI‑driven upselling potential support a positive outlook.
Rezolve AI PLC (NASDAQ:RZLV) provides an enterprise AI platform, The Brain Suite, for “Agentic Commerce,” transforming how businesses engage customers by using AI to handle search, personalization, transactions (including crypto via Tether), and fulfillment in a seamless, conversational flow from discovery to checkout, boosting efficiency and revenue for retailers.
2. Inventiva S.A. (NASDAQ:IVA)
Share price: $4.46
Analysts upside potential: 300.45%
Number of hedge fund holders: 5
Inventiva S.A. (NASDAQ:IVA) is one of the best multibagger penny stocks to buy right now. Inventiva (NASDAQ:IVA) commands a consensus Buy rating on Wall Street. The average price target for the stock is $17.86, implying 300.45% upside potential.
On November 25, Piper Sandler analyst Yasmeen Rahimi reiterated a Buy rating and a $26 price target. The positive stance comes on the heels of the company generating €4.5 million in revenue for the first nine months of the year, a significant improvement from none for the same period last year.
The clinical-stage biopharmaceutical company had €97.6 million in cash and cash equivalents, a slight improvement from €96.6 million at the end of 2024. In November, it completed a public offering of 44.81 million shares, raising €139.3 million in net proceeds. Under the current cost structure and forecasted expenditures, Inventiva remains in a solid financial position to finance operations through the end of the first quarter of 2027.
Meanwhile, analysts at Guggenheim reiterated a Buy rating on the stock but cut the price target to $11 from $13. The price target cut is in response to the company completing the public offering to finance the NATiV3 Phase 3 trial.
Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company focused on the research and development of oral small-molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
1. Invivyd, Inc. (NASDAQ:IVVD)
Share price: $2.22
Analysts upside potential: 350.45%
Number of hedge fund holders: 20
Invivyd Inc. (NASDAQ:IVVD) is one of the best multibagger penny stocks to buy right now. On November 24, the company selected VBY329 as a monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in neonates, infants, and children.
The company generated the investigational antibody from its proprietary antibody discovery technology for use in high-value infectious diseases. In vitro testing, VBY329 has already demonstrated 1.5-fold greater antiviral potency than clesrovimab. Consequently, the company is moving it into IND-enabling processes with the goal of IND readiness in the second half of the following year.
“We are proud of our progress with VBY329,” noted Marc Elia, Chairman of the Invivyd Board of Directors. “RSV prophylaxis among babies and children under 24 months is a blockbuster, rapidly growing pharmaceutical market that frees our youngest, most vulnerable Americans, including newborns, from a high-burden pathogen, all without requiring the immune stimulation of a vaccine.
Meanwhile, D. Boral Capital downgraded Invivyd to a Hold from a Buy following the nomination of next-generation RSV antibody VBY329 with IND readiness targeted for the second half of 2026. According to the research, the downgrade fully reflects the pipeline and balance sheet expectations.
Invivyd, Inc. (NASDAQ:IVVD) creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary, industry-unique integrated technology platform to assess, monitor, develop, and adapt to create best-in-class antibodies.
While we acknowledge the potential of Invivyd, Inc. (NASDAQ:IVVD) to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IVVD and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: Billionaire David Tepper’s Top 12 Stock Picks Heading into 2026 and 12 Best Industrial Stocks to Buy According to Wall Street Analysts.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
